News
This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...
The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback